CRUK CRCTU Core Funding

Fisher, Benjamin (Co-Investigator)
Billingham, Lucinda (Researcher)
Bach, Simon (Researcher)
Kearns, Pamela (Co-Investigator)
Pratt, Guy (Researcher)
Bowden, Sarah (Principal Investigator)
Rea, Daniel (Researcher)
Middleton, Gary (Co-Investigator)
Gates, Simon (Researcher)

Short title	CRUK CRCTU Core Funding
Status	Active
Effective start/end date	1/10/23 → 30/09/28

Funding

Cancer Research UK

9 Article
1 Preprint

Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocol
Fisher, B. A., Rowe, A., Hodson, C., Wilkhu, M., Williams, E., Turner, E., Allard, A., Blake, T., Bombardieri, M., Cope, A. P., Dubey, S., Mankia, K., Malley, T., Moore, O., Payne, M., Plummer, R., Tilby, M., Tillett, T., Wong, E. & Wu, Y. & 4 others, Filer, A., Pratt, A., Pallan, L. & Homer, V., 3 Mar 2026, In: BMJ Open. 16, 3, 10 p., e116847.
Research output: Contribution to journal › Article › peer-review

Open Access
File
6 Downloads (Pure)
Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trial
Vormoor, B., Savage, J., Kristunas, C., Johnson, S., Blanco, M. N. F., Shenton, G., Lancaster, D., Castleton, A., Fielding, A. K., Latif, A.-L., Morley, N., Strullu, M., Tuckuviene, R., Kearns, P., Jennings, C., Barnett, S., Veal, G. J., Irving, J., Billingham, L. & Menne, T. & 1 others, Vormoor, J., Jun 2026, In: EJC Paediatric Oncology. 7, 10 p., 100489.
Research output: Contribution to journal › Article › peer-review

Open Access
File
27 Downloads (Pure)
Results of the Childhood Cancer and Leukaemia Group's United Kingdom Relapsed Wilms Tumour Trial
Vaidya, S. J., Moroz, V., Hale, J., Pavasovic, V., Hobson, R., Sartori, P., Saunders, D., Powis, M., Vujanic, G. M., Baker, S. & Pritchard-Jones, K., 15 Mar 2026, (E-pub ahead of print) In: Pediatric Blood & Cancer. 8 p., e70191.
Research output: Contribution to journal › Article › peer-review

Open Access
File
1 Downloads (Pure)

CRUK CRCTU Core Funding

Project Details

Funding

Fingerprint

Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocol

Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trial

Results of the Childhood Cancer and Leukaemia Group's United Kingdom Relapsed Wilms Tumour Trial

CRUK CRCTU Core Funding

Project Details

Funding

Fingerprint

Research output

Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocol

Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trial

Results of the Childhood Cancer and Leukaemia Group's United Kingdom Relapsed Wilms Tumour Trial